SCHEMBL922941

SCHEMBL922941

NC1=NN=C(N)C1=NNc1cccc2cccnc12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 14/20 0.51
KMT2A Q03164 14/20 0.51
TDP1 Q9NUW8 12/20 0.51
MAPT P10636 11/20 0.51
RAB9A P51151 10/20 0.51
SMN1; SMN2 Q16637 9/20 0.51
NPC1 O15118 8/20 0.51
KDM4E B2RXH2 5/20 0.51
ALDH1A1 P00352 5/20 0.51
GAA P10253 9/20 0.48
RELA Q04206 6/20 0.48
NFKB1 P19838 5/20 0.48
NFKB2 Q00653 5/20 0.48
LMNA P02545 4/20 0.48
L3MBTL1 Q9Y468 3/20 0.48
HTT P42858 3/20 0.48
GLO1 Q04760 2/20 0.48
ALOX15 P16050 1/20 0.48
CYP1A2 P05177 1/20 0.48
CYP3A4 P08684 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL921882 0.78 MEN1 (0.46) MEN1KMT2ATDP1MAPTSMN1; SMN2
SCHEMBL922339 0.76 KDM4E (0.42) MAPTRAB9ANPC1KDM4EALDH1A1
SCHEMBL923259 0.74 LMNA (0.49) MEN1KMT2AMAPTSMN1; SMN2KDM4E
SCHEMBL923564 0.73 CYP3A4 (0.35) TDP1MAPTRAB9ASMN1; SMN2NPC1
SCHEMBL2481131 0.71 CYP3A4 (0.61) MEN1KMT2ATDP1MAPTSMN1; SMN2
SCHEMBL31130165 0.71 CYP3A4 (0.61) MEN1KMT2ATDP1MAPTSMN1; SMN2
SCHEMBL921530 0.71 NPC1 (0.49) MEN1KMT2ATDP1MAPTRAB9A
SCHEMBL379216 0.70 GLO1 (0.59) MEN1KMT2ATDP1MAPTRAB9A
Hydrochloric Acid SCHEMBL28066152 0.70 CYP3A4 (0.59) MEN1KMT2ATDP1MAPTSMN1; SMN2
SCHEMBL25291704 0.69 RAB9A (0.36) MEN1KMT2ATDP1MAPTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110237783-A1 HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS Valocor Therapeutics, Inc. (CA) 2011-09-29 US claimed
US-7105503-B2 Pyrazole compounds QLT INC. (CA) 2006-09-12 US claimed
US-20050272709-A1 Immugenic compositions and diagnostic and therapeutic uses thereof DERMIRA (CANADA), INC. 2005-12-08 US claimed
EP-1450791-A1 HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS Kinetek Pharmaceuticals, Inc. (CA) 2004-09-01 EP claimed
WO-2003045379-A1 HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS KINETEK PHARMACEUTICALS, INC. (CA) 2003-06-05 WO claimed
US-20030060453-A1 Pyrazole compounds DERMIRA (CANADA), INC. 2003-03-27 US claimed
US-20140107125-A1 HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS DERMIRA (CANADA), INC. (US) 2014-04-17 US disclosed
US-8445694-B2 Hydrazonopyrazole derivatives and their use as therapeutics DERMIRA (CANADA), INC. (US) 2013-05-21 US disclosed
US-20110237783-A1 HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS Valocor Therapeutics, Inc. (CA) 2011-09-29 US disclosed
US-7875728-B2 tert-butyl-[5-methyl-4-(phenylhydrazono)-4H-pyrazol-3-yl]amine; 4-(3-fluorophenylhydrazono)-5-methyl-2H-pyrazol-3-ylamine; demonstrate anti-proliferative activity, and may promote apoptosis in cells lacking normal regulation of cell cycle and death Valocor Therapeutics, Inc. (CA) 2011-01-25 US disclosed
US-7105503-B2 Pyrazole compounds QLT INC. (CA) 2006-09-12 US disclosed
US-20050272709-A1 Immugenic compositions and diagnostic and therapeutic uses thereof DERMIRA (CANADA), INC. 2005-12-08 US disclosed
EP-1450791-A1 HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS Kinetek Pharmaceuticals, Inc. (CA) 2004-09-01 EP disclosed
WO-2003045379-A1 HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS KINETEK PHARMACEUTICALS, INC. (CA) 2003-06-05 WO disclosed
US-20030060453-A1 Pyrazole compounds DERMIRA (CANADA), INC. 2003-03-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237783-A1 HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS CDK4, CCNI, BCL2 MEN1 3936/4885KMT2A 2931/4885TDP1 646/4885
US-20140107125-A1 HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS CDK4, CCNI, BCL2 MEN1 3936/4885KMT2A 2931/4885TDP1 646/4885
US-20050272709-A1 Immugenic compositions and diagnostic and therapeutic uses thereof MKI67, CDK4, CCNC MEN1 1844/4885KMT2A 4148/4885TDP1 286/4885
US-20030060453-A1 Pyrazole compounds CCNC, MKI67, CDC25C MEN1 3439/4885KMT2A 3543/4885TDP1 632/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.